A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Navitoclax (Primary) ; Erlotinib; Irinotecan
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- 04 Jun 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 May 2013 as reported by ClinicalTrials.gov.